TITLE

Recurrent oral cancer: current and emerging therapeutic approaches

AUTHOR(S)
da Silva, Sabrina Daniela; Hier, Michael; Mlynarek, Alex; Kowalski, Luiz Paulo; Alaoui-Jamali, Moulay A.
PUB. DATE
July 2012
SOURCE
Frontiers in Pharmacology;Jul2012, Vol. 3, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
88094017

 

Related Articles

  • Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mishra, Rajakishore // Molecular Cancer;2010, Vol. 9, p144 

    Despite progress in treatment approaches for oral cancer, there has been only modest improvement in patient outcomes in the past three decades. The frequent treatment failure is due to the failure to control tumor recurrence and metastasis. These failures suggest that new targets should be...

  • Understanding Epithelial-Mesenchymal Transition may Reveal Novel Therapeutic Targets for Oral Squamous Cell Carcinoma. Munshi, Hidayatullah G.; Stack, M. Sharon // Current Cancer Therapy Reviews;2011, Vol. 7 Issue 2, p104 

    Worldwide more than 350,000 patients will be diagnosed with oral cancer this year; however, the survival of patients with oral cancer has not changed significantly over the last 30 years. Recent reports have demonstrated that epithelial-mesenchymal transition (EMT) not only contributes to cancer...

  • Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer). YOSHIMURA, KIYOSHI; OLINO, KELLY; EDIL, BARISH H.; SCHULICK, RICHARD D.; OKA, MASAAKI // Surgery Today;May2010, Vol. 40 Issue 5, p404 

    Current treatment modalities of surgical resection and chemotherapy against cancers have improved survival. However, mortality from tumor recurrence remains high. Immunotherapy and gene therapy are potential additions to the treatment arsenal in the care of cancer patients. These novel...

  • Targeting Cancer Stem Cells: How to Switch Off Immortality. Prado, Ana M. // Recent Patents on Endocrine, Metabolic & Immune Drug Discovery;Nov2009, Vol. 3 Issue 3, p225 

    Despite the fact that cancer is a leading cause of death world wide, a clear understanding of the causes, processes, and epidemiology of cancer remains elusive. Nevertheless key players are being identified, such as cancer stem cells, a subset of cells that are capable of self-renewal and...

  • Recurrence of nasopharyngeal carcinoma in the mastoid region: Therapeutic approach of a rare clinical entity. ÜÇÜNCÜ KEFELİ, Ayşegül; ATASOY, Beste Melek; ÖZGEN, Zerrin; SARI, Murat; DEDE, Fuat; DANE, Faysal // Marmara Medical Journal;May2014, Vol. 27 Issue 2, p129 

    Mastoid region recurrence is a rare entity for nasopharyngeal cancer. This paper presents a patient with an isolated mastoid recurrence following definitive treatment and discusses the therapeutic approach which may help in the treatment of such cases.

  • Ascenta Raises $50M For Apoptosis Phase II Trials. Morrison, Trista // BioWorld Today;4/11/2007, Vol. 18 Issue 70, p1 

    The article reports on the fund raised by Ascenta Therapeutics Inc. from the apoptosis drug AT-101 Phase II cancer trials. The author says interest in apoptosis-based cancer drugs has emerged based on recognition that cancer is a disease of unregulated cell survival. AT-101 approaches apoptosis...

  • Tumor vaccines: Fiction to fact. Aneja, Tania; Puri, Abhiney; Bansal, Sucheta; Guleria, Meetali // Journal of Oral & Maxillofacial Pathology (0973029X);2014 Special Issue, Vol. 18, pS72 

    Oral cancer is one of the major reasons for morbidity and mortality worldwide. It encompasses a range of benign and malignant tumors arising from various diverse and complex structures that have major physiological functions like speech and swallowing and esthetic importance. Despite significant...

  • Immunotherapy for Prostate Cancer Enters Its Golden Age. Boikos, Sosipatros A.; Antonarakis, Emmanuel S. // Clinical Medicine Insights: Oncology;2012, Issue 6, p263 

    In the United States, prostate cancer is the most frequent malignancy in men and ranks second in terms of mortality. Although recurrent or metastatic disease can be managed initially with androgen ablation, most patients eventually develop castration-resistant disease within a number of years,...

  • Immunotherapy for Prostate Cancer Enters Its Golden Age. Boikos, Sosipatros A.; Antonarakis, Emmanuel S. // Clinical Medicine Insights: Oncology;2012, Issue 6, p263 

    In the United States, prostate cancer is the most frequent malignancy in men and ranks second in terms of mortality. Although recurrent or metastatic disease can be managed initially with androgen ablation, most patients eventually develop castration-resistant disease within a number of years,...

  • Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options. Moreno, Antonio José Conde; Albiach, Carlos Ferrer; Soria, Rodrigo Muelas; Vidal, Verónica González; Gómez, Raquel García; Antequera, María Albert // Radiation Oncology;2014, Vol. 9 Issue 1, p36 

    There are various subgroups of patients with metastatic prostate cancer: polymetastatic, oligometastatic, or oligo-recurrent cancers whose progression follows different courses and for whom there are different treatment options. Knowledge of tumor dissemination pathways and different genetic and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics